

Correction: Pan PI3K Inhibitor Prodrug for Cancer Therapy

The article on pan PI3K inhibitor prodrug for cancer therapy in the January 1, 2008 issue of *Cancer Research* (1) should have included the following conflict of interest statement: D.L. Durden would like to disclose a financial interest in Semafore Pharmaceuticals. The terms of the arrangement have been reviewed and approved by Emory University in accordance with the conflict of interest policies.

1. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu H-K, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. *Cancer Res* 2008;68:206–15.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Correction: Pan PI3K Inhibitor Prodrug for Cancer Therapy

Cancer Res 2008;68:6030.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/68/14/6030.1>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/68/14/6030.1.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/68/14/6030.1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.